Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.79 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.71 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL615385 | 0.94 | NFE2L2 (0.77) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL5182341 | 0.92 | NFE2L2 (0.69) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL21798669 | 0.90 | NFE2L2 (0.66) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL14518616 | 0.90 | NFE2L2 (0.66) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL7870072 | 0.90 | NFE2L2 (0.66) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL1603723 | 0.89 | NFE2L2 (1.00) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL5500710 | 0.89 | NFE2L2 (1.00) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL1045608 | 0.88 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL5205155 | 0.88 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 | |
| SCHEMBL1045609 | 0.88 | NFE2L2 (0.64) | NFE2L2CYP1A1CYP1A2CYP1B1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141224-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | FIGENE, LLC | 2023-05-11 | — | — | US | claimed |
| EP-4142751-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | Figene, LLC (US) | 2023-03-08 | — | — | EP | claimed |
| WO-2021202032-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | FIGENE, LLC (US) | 2021-10-07 | — | — | WO | claimed |
| WO-2018210880-A1 | STILBENES FOR PRE-HARVEST TREATMENT AND CROP PROTECTION | EVOLVA SA (CH) | 2018-11-22 | — | — | WO | claimed |
| WO-2018210872-A1 | STILBENES FOR POST-HARVEST TREATMENT AND FOOD PRESERVATION AND/OR SHELF LIFE EXTENSION | EVOLVA SA (CH) | 2018-11-22 | — | — | WO | claimed |
| US-20160215306-A1 | METHOD FOR PRODUCING MODIFIED RESVERATROL | EVOLVA SA (CH) | 2016-07-28 | — | — | US | claimed |
| EP-3039132-A2 | A METHOD FOR PRODUCING MODIFIED RESVERATROL | Evolva SA (CH) | 2016-07-06 | — | — | EP | claimed |
| WO-2015028324-A2 | A METHOD FOR PRODUCING MODIFIED RESVERATROL | EVOLVA SA (CH) | 2015-03-05 | — | — | WO | claimed |
| EP-2060255-A2 | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection | The Regents Of The University Of California (US) | 2009-05-20 | — | — | EP | claimed |
| EP-1450819-A4 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE, AND TRANSPLANT REJECTION | UNIV CALIFORNIA (US) | 2008-01-23 | — | — | EP | claimed |
| US-20040242500-A1 | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-02 | — | — | US | claimed |
| EP-1450819-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE, AND TRANSPLANT REJECTION | The Regents of the University of California (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2003039557-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE, AND TRANSPLANT REJECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-05-15 | — | — | WO | claimed |
| WO-2026102249-A1 | TNF RECEPTOR SUPERFAMILY AGONIST FUSION POLYPEPTIDES | ANKYRA THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12606872-B2 | Methods for stratification and early detection of advanced adenoma and/or colorectal cancer using DNA methylation markers | Universal Diagnostics, S.A. (ES) | 2026-04-21 | — | — | US | disclosed |
| EP-4691558-A2 | TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS | University Court of The University of Dundee (GB) | 2026-02-11 | — | — | EP | disclosed |
| WO-2003039557-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE, AND TRANSPLANT REJECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-05-15 | — | — | WO | disclosed |
| US-6552213-B1 | Oxidation and halogenation of such as 3,4',5-tribenzyloxy-dibenzylsulfide; reductive dehalogenation desulfonation; hydrolysis | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED, INDIA (IN) | 2003-04-22 | — | — | US | disclosed |
| US-5272270-A | Process for the preparation of 1-alkylisoquinoline derivatives | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1993-12-21 | — | — | US | disclosed |
| EP-0471303-A1 | Process for the preparation of 1-alkylisoquinoline derivatives | Consortium für elektrochemische Industrie GmbH (DE) | 1992-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242500-A1 | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection | TNF, HLA-DRB1, IL5 | NFE2L2 730/4885CYP1A1 1344/4885CYP1A2 1036/4885 |
| US-12606872-B2 | Methods for stratification and early detection of advanced adenoma and/or colorectal cancer using DNA methylation markers | DNMT3L, DNMT3A, UNG | NFE2L2 2415/4885CYP1A1 1642/4885CYP1A2 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.